

# Cabozantinib cancer drug

September 15, 2021

**In news**— Recently, drug firm BDR Pharmaceuticals has launched generic Cabozantinib cancer drug.

## About the Cabozantinib cancer drug-

- Cabozantinib is used for treating patients with progressive, metastatic medullary thyroid cancer and as a second-line treatment for renal cell carcinoma apart from treating hepatocellular carcinoma.
- The drug is available in the strengths of 20 mg, 40 mg and 60 mg.
- The drug works by blocking (inhibiting) the signals inside cancer cells that make them grow and divide.
- In several trials like Celestial (double-blind phase III trial), Phase III Meteor trials, CABOZANIB has shown better PFS (Progression-Free Survival).
- As DCGI approved BDR Pharma's Cabozantinib to be put into medicinal use, the company claimed that it will soon make it available in the market for treatment.

## What is metastatic medullary thyroid cancer?

- It is a neuroendocrine tumor that is derived from C cells of the thyroid gland.
- It is a rare aggressive tumor, known to metastasize to lymph nodes, liver, bones, and lungs.

## What is renal cell carcinoma?

- Renal cell carcinoma (RCC) is also called hypernephroma, renal adenocarcinoma, or renal or kidney cancer.
- It's the most common kind of kidney cancer found in adults.
- Smoking and misuse of certain pain medicines can affect the risk of renal cell cancer.

## **What is hepatocellular carcinoma?**

- It is the most **common type of primary liver cancer.**
- It occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection.

## **About BDR group-**

- BDR group is recognized as a “niche” player in manufacturing of Pharmaceutical APIs and renowned new age formulations.
- The group is complemented majorly by its two companies – BDR Pharmaceuticals International Pvt Ltd and BDR Life sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.